Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients

被引:0
|
作者
Zahed, L [1 ]
Mourad, FH [1 ]
Alameddine, R [1 ]
Aoun, S [1 ]
Koussa, S [1 ]
Taher, A [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Pathol & Lab Med, Beirut, Lebanon
关键词
oral chelation; psychosocial status; thalassaemia;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
beta-Thalassemia requires life-long treatment, including regular blood transfusion and daily iron chelation by desferrioxamine, which places considerable burden on the social and psychological life of patients. It is expected that oral chelation therapy, which is easier to administer, would improve their psychosocial status. In this sutdy, interviews were conducted with a series of 44 patients recently placed on oral chelation therapy to evaluate their reactions to the new treatment. Eighty-six per cent of patients complied better with the oral chelation therapy. Fifty per cent of patients mentioned that relief from the desferrioxamine pump was the major improvement, while 47% felt psychologically better. Fifty per cent of patients noted improvements in their relationships, while 63% noted increased social activities. Evaluation of a larger sample of patients over a longer period of time is needed in order to confirm the favourable results obtained in this study.
引用
收藏
页码:333 / 339
页数:7
相关论文
共 50 条
  • [31] ORAL IRON CHELATION-THERAPY WITH DEFERIPRONE - MONITORING OF BIOCHEMICAL, DRUG AND IRON EXCRETION CHANGES
    KONTOGHIORGHES, GJ
    BARTLETT, AN
    SHEPPARD, L
    BARR, J
    NORTEY, P
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1995, 45-1 (01): : 65 - 69
  • [32] Deferiprone (L1) fails to mobilize iron and promotes iron cardiotoxicity at suboptimal L1/iron concentrations.
    Hershko, C
    Link, G
    Pinson, A
    Konijn, AM
    BLOOD, 1997, 90 (10) : 33 - 33
  • [33] Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)
    CastriotaScanderbeg, A
    Sacco, M
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (02) : 254 - 255
  • [34] Deferiprone (L1), an oral iron chelator - A novel approach to ameliorate experimental colitis.
    Ablin, J
    Shalev, O
    Karmeli, F
    Rachmilewitz, D
    GASTROENTEROLOGY, 1997, 112 (04) : A918 - A918
  • [35] Deferiprone (L1), an oral iron chelator - A novel approach to ameliorate gastric damage.
    Ablin, J
    Shalev, O
    Karmeli, F
    Rachmilewitz, D
    GASTROENTEROLOGY, 1997, 112 (04) : A52 - A52
  • [36] Subcutaneous iron chelation therapy, oral iron chelation therapy, or both in patients with thalassemia?
    Babrs, Gihan M.
    Abd El-Hakeem, Mohammed A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2013, 38 (02): : 51 - 55
  • [37] Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
    Makis, Alexandros
    Chaliasos, Nikolaos
    Alfantaki, Sapfo
    Karagouni, Paraskevi
    Siamopoulou, Antigone
    ANEMIA, 2013, 2013
  • [38] Clinical audit: compliance with iron chelation therapy in adult thalassaemia patients
    Khan, A. K.
    Wright, C. W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 76 - 76
  • [39] RESULTS OF LONG-TERM DEFERIPRONE (L1) THERAPY - A REPORT BY THE INTERNATIONAL STUDY-GROUP ON ORAL IRON CHELATORS
    ALREFAIE, FN
    HERSHKO, C
    HOFFBRAND, AV
    KOSARYAN, M
    OLIVIERI, NF
    TONDURY, P
    WONKE, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (01) : 224 - 229
  • [40] RESULTS OF LONG-TERM DEFERIPRONE (L1) THERAPY - A REPORT BY THE INTERNATIONAL STUDY-GROUP ON ORAL IRON CHELATORS
    HERSHKO, C
    HOFFBRAND, AV
    KOSARYAN, M
    OLIVIERI, NF
    ALREFAIE, FN
    TONDURY, P
    WONKE, B
    BLOOD, 1994, 84 (10) : A257 - A257